Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30994254 | 0.89 | EGFR (0.34) | EGFR | |
| SCHEMBL30994302 | 0.84 | GABRB3 (0.37) | HPGDKMT2A | |
| SCHEMBL22655143 | 0.84 | L3MBTL1 (0.35) | KDM4EALDH1A1HPGDPPARD | |
| SCHEMBL23899711 | 0.84 | NOTUM (0.33) | KDM4EHTTKMT2AEGFR | |
| SCHEMBL30375605 | 0.84 | L3MBTL1 (0.35) | KDM4EALDH1A1HPGDPPARD | |
| SCHEMBL22654828 | 0.80 | ABCG2 (0.37) | KMT2AABCG2RAPGEF4 | |
| SCHEMBL30743622 | 0.80 | ABCG2 (0.37) | KMT2AABCG2RAPGEF4 | |
| SCHEMBL30994374 | 0.80 | PPARD (0.32) | PPARD | |
| SCHEMBL30994139 | 0.79 | PTPN1 (0.30) | — | |
| SCHEMBL531949 | 0.78 | RAPGEF4 (0.42) | ALDH1A1AGBL2RAPGEF4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4658640-A1 | PYRIDIN-2(1H)-ONES AND PYRIMIDIN-4(3H)-ONES AS NLRP3 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4656635-A1 | SUBSTITUTED BENZENE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4562009-A1 | NOVEL COMPOUNDS | AC Immune SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4493556-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119301116-A | NLRP3 modulators | 祖玛珍生物科学有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024160693-A1 | PYRIDIN-2(1H)-ONES AND PYRIMIDIN-4(3H)-ONES AS NLRP3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-08 | — | — | WO | disclosed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| WO-2024157953-A1 | SUBSTITUTED BENZENE COMPOUND | 第一三共株式会社 | 2024-08-02 | — | — | WO | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240101563-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-03-28 | — | — | US | disclosed |
| WO-2024023266-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023178099-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | KDM4E 3755/4885ALDH1A1 3601/4885HPGD 1295/4885 |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | KDM4E 2198/4885ALDH1A1 3173/4885HPGD 1920/4885 |
| US-20240101563-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | KDM4E 4607/4885ALDH1A1 2336/4885HPGD 1267/4885 |
| US-20230295113-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | KDM4E 4253/4885ALDH1A1 2633/4885HPGD 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.